Photo from The START Center for Cancer Research/LinkedIn
Jun 23, 2024, 13:45
START Midwest team has successfully dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial
The START Center for Cancer Research shared on LinkedIn: .
“We are proud to announce that our START Midwest team has successfully dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial.
This innovative study, in collaboration with Loxo@Lilly, evaluates an antibody drug conjugate targeting folate receptor alpha with a topoisomerase 1 inhibitor payload.
Dr. Nehal Lakhani, Director of Clinical Research at START Midwest, shares, ‘Dosing the first cohort in the LOXO-FRA-24001 trial marks a significant achievement for our team. This study exemplifies our ongoing commitment to pioneering advanced treatments in oncology.’
Read more about this study.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46